trial · primary record
Cevostamab
Multiple Myeloma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 90 |
| Primary completion | 2027-02-26 |
| Primary endpoint | Objective Response Rate (ORR) as Determined by the Investigator |
| Registry ID | NCT05535244 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:42.546Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05535244
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.